FDA commissioner’s drug review plan sparks alarm across the agency

There’s concern that FDA drug reviews—long pegged to objective standards and procedures—have become open to political interference.

The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the agency, stoking worries that the plan may run afoul of legal, ethical, and scientific standards long used to vet the safety and effectiveness of new medicines.